Bioxcel Therapeutics, INC 8-K filings

BioXcel Therapeutics has detailed the design of its upcoming Phase 3 TRANQUILITY In-Care trial to evaluate BXCL501 for treating agitation in Alzheimer's dementia patients.

BioXcel Therapeutics has entered into a securities purchase agreement for a registered direct offering to raise approximately $25 million.

BioXcel Therapeutics announced its 2023 financial results and provided updates on its late-stage clinical programs for BXCL501, including plans to generate additional efficacy data for Alzheimer's agitation.

BioXcel Therapeutics is focusing on expanding its neuroscience pipeline, particularly with at-home treatments for agitation, and exploring strategic options for its immuno-oncology assets.

BioXcel Therapeutics has amended its credit agreement, waiving a going concern qualification, and received Fast Track designation from the FDA for its cancer treatment program.

BioXcel Therapeutics is planning additional Phase 3 trials for BXCL501 in at-home settings for agitation related to dementia, bipolar disorders, and schizophrenia, while also reporting an estimated $61.6 million in cash as of January 31, 2024.

BioXcel Therapeutics has obtained new patents for its dexmedetomidine-based agitation treatments, potentially extending market exclusivity until 2043.